Inflammatory bowel disease patients are at risk of hepatitis B infection. Data on this prevalence from South Asia are limited. We conducted a prospective study comprising of 76 inflammatory bowel disease patients between October 2013 and August 2014. Prevalence of hepatitis B surface antigen in inflammatory bowel disease, ulcerative colitis and Crohn’s disease patients were 2.6%, 2.4% and 3% respectively and that of markers of hepatitis B exposure (hepatitis B surface antigen /hepatitis B core antibody) were 11.8%, 14.3% and 9.1% respectively. Risk factors found significantly more common in those positive for viral markers compared to those negative were age, non-inflammatory bowel disease related surgery and hospital admission. Only 7(9.2%) had completed hepatitis B vaccination. There is a need to create awareness among physicians regarding the importance of hepatitis B screening and vaccination in inflammatory bowel disease patients.
SoodAMidhaV. Epidemiology of inflammatory bowel disease in Asia. Indian J Gastroenterol Off J Indian Soc Gastroenterol2007; 26: 285–289.
2.
VigetNVernier-MassouilleGSalmon-CeronD, et al.Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut2008; 57: 549–558.
3.
LokASF. Chronic hepatitis B. N Engl J Med2002; 346: 1682–1683.
4.
LavanchyD. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat2004; 11: 97–107.
5.
LahariyaCSubramanyaBPSoslerS. An assessment of hepatitis B vaccine introduction in India: lessons for roll out and scale up of new vaccines in immunization programs. Indian J Public Health2013; 57: 8–14.
6.
ZeitzJMullhauptBFruehaufH, et al.Hepatic failure due to hepatitis B reactivation in a patient with ulcerative colitis treated with prednisone. Hepatology2009; 50: 653–654.
7.
SaccoRBertiniMBresciG, et al.Entecavir for hepatitis B virus flare treatment in patients with Crohn’s disease. Hepatogastroenterology2010; 57: 242–245.
8.
EsteveMSaroCGonzález-HuixF, et al.Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut2004; 53: 1363–1365.
9.
LorasCSaroCGonzalez-HuixF, et al.Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol2009; 104: 57–63.
10.
MelmedGYIppolitiAFPapadakisKA, et al.Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol2006; 101: 1834–1840.
11.
GuptaAMacraeFAGibsonPR. Vaccination and screening for infections in patients with inflammatory bowel disease: a survey of Australian gastroenterologists. Intern Med J2011; 41: 462–467.
12.
MelmedGY. Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. Inflamm Bowel Dis2009; 15: 1410–1416.
13.
GisbertJPVillagrasaJRRodríguez-NogueirasA, et al.Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol2012; 107: 1460–1466.
14.
Vida PérezLGómez CamachoFGarcía SánchezV, et al.[Adequate rate of response to hepatitis B virus vaccination in patients with inflammatory bowel disease]. Med Clin2009; 132: 331–335.
15.
TerraultNALokASFMcMahonBJ, et al.Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology2018; 67: 1560–1599.
16.
European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol2017; 67: 370–398.
17.
RahierJFMagroFAbreuC, et al.Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis2014; 8: 443–468.
18.
KatsanosKHTsianosVEZoisCD, et al.Inflammatory bowel disease and hepatitis B and C in Western Balkans: a referral centre study and review of the literature. J Crohns Colitis2010; 4: 450–465.
19.
HuangMLXuXTShenJ, et al.Prevalence and factors related to hepatitis B and C infection in inflammatory bowel disease patients in China: a retrospective study. J Crohns Colitis2014; 8: 282–287.
20.
HarshPGuptaVKediaS, et al.Prevalence of hepatitis B, hepatitis C and human immunodeficiency viral infections in patients with inflammatory bowel disease in north India. Intest Res2017; 15: 97–102.
21.
KimESChoKBParkKS, et al.Prevalence of hepatitis-B viral markers in patients with inflammatory bowel disease in a hepatitis-B-endemic area: inadequate protective antibody levels in young patients. J Clin Gastroenterol2014; 48: 553–558.
22.
SatsangiJSilverbergMSVermeireS, et al.The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut2006; 55: 749–753.
23.
AsimMAliRKhanLA, et al.Significance of anti-HBc screening of blood donors and its association with occult hepatitis B virus infection: Implications for blood transfusion. Indian J Med Res2010; 132: 312–317.
24.
IsmailAMDevakumarSAnantharamR, et al.Low frequency of occult hepatitis B infection in anti-HBc seropositive blood donors: experience from a tertiary care centre in South India. Blood Transfus2012; 10: 230–232.
25.
SinghHAggarwalRSinghRL, et al.Frequency of infection by hepatitis B virus and its surface mutants in a northern Indian population. Indian J Gastroenterol Off J Indian Soc Gastroenterol2003; 22: 132–137.
26.
BianconeLPaviaMDel Vecchio BlancoG, et al.Hepatitis B and C virus infection in Crohn’s disease. Inflamm Bowel Dis2001; 7: 287–294.
27.
ChevauxJ-BNaniAOussalahA, et al.Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflamm Bowel Dis2010; 16: 916–924.
28.
TolentinoYFMFogaçaHSZaltmanC, et al.Hepatitis B virus prevalence and transmission risk factors in inflammatory bowel disease patients at Clementino Fraga Filho University hospital. World J Gastroenterol WJG2008; 14: 3201–3206.
29.
LeungWKLiuKSSetoW-KW, et al.Factors for hepatitis B vaccination and abnormal liver function in Chinese patients with inflammatory bowel disease: a single center experience. J Dig Dis2013; 14: 596–603.
30.
PapaAFeliceCMarzoM, et al.Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents. J Crohns Colitis2013; 7: 113–119.
31.
Ben MusaRGampaABasuS, et al.Hepatitis B vaccination in patients with inflammatory bowel disease. World J Gastroenterol WJG2014; 20: 15358–15366.
32.
ParkSHYangS-KLimY-S, et al.Clinical courses of chronic hepatitis B virus infection and inflammatory bowel disease in patients with both diseases. Inflamm Bowel Dis2012; 18: 2004–2010.
33.
Chan HCH, Wong VWS, Wong GLH, et al. Prevalence of hepatitis B and clinical outcomes in inflammatory bowel disease patients in a viral-endemic region. BMC Gastroenterol 2016; 16(1): 100.
34.
HeYXuPChenY, et al.Prevalence and influences of hepatitis B virus infection on inflammatory bowel disease: a retrospective study in southern China. Int J Clin Exp Med2015; 8: 8078–8085.
35.
GohKTDingJLMonteiroEH, et al.Hepatitis B infection in households of acute cases. J Epidemiol Community Health1985; 39: 123–128.
36.
IqbalKKlevensRMKainerMA, et al.Epidemiology of acute hepatitis B in the United States from population-based surveillance, 2006–2011. Clin Infect Dis Off Publ Infect Dis Soc Am2015; 61: 584–592.
37.
HauriAMArmstrongGLHutinYJF. The global burden of disease attributable to contaminated injections given in health care settings. Int J STD AIDS2004; 15: 7–16.
38.
AbbasZSiddiquiAR. Management of hepatitis B in developing countries. World J Hepatol WJH2011; 3: 292–299.
39.
ChaparroMVillagrasaJRNogueirasAR, et al.S1175 immune response to hepatitis B vaccination in patients with inflammatory bowel disease. Gastroenterology2010; 138: S–197.
40.
CunhaI de SSilvaTC daMallutaÉF, et al.Seroconversion analysis after habitual hepatitis B vaccination scheme in patients with inflammatory bowel diseases. Arq Gastroenterol2020; 57: 69–73.
41.
AltunözMESenateşEYeşilA, et al.Patients with inflammatory bowel disease have a lower response rate to HBV vaccination compared to controls. Dig Dis Sci2012; 57: 1039–1044.
